Related Experiment Videos

Characterization of transforming growth factor-beta-resistant subclones isolated from a transforming growth

K M Mulder1, M K Ramey, N M Hoosein

  • 1Bristol-Baylor Laboratory, Department of Pharmacology, Baylor College of Medicine, Houston, Texas 77030.

Cancer Research
|December 15, 1988
PubMed

Insights

Researchers identified colon cancer cell subclones resistant to transforming growth factor-beta (TGF-beta). These cells, while still binding TGF-beta, lost its typical inhibitory effects on proliferation and gene expression, indicating specific resistance mechanisms.

Area of Science:

  • Oncology
  • Cell Biology
  • Molecular Biology

Background:

  • Transforming growth factor-beta (TGF-beta) is known to inhibit proliferation in MOSER human colon carcinoma cells.
  • Understanding resistance mechanisms to TGF-beta is crucial for cancer therapy.

Purpose of the Study:

  • To isolate and characterize spontaneously arising subclones of MOSER cells that are refractory to TGF-beta's inhibitory effects.
  • To investigate the specificity of this refractoriness.

Main Methods:

  • Isolation and characterization of TGF-beta-resistant MOSER cell subclones.
  • Assessing cellular proliferation in monolayer and soft agarose cultures.
  • Measuring extracellular fibronectin and c-myc protooncogene expression.
  • Evaluating TGF-beta binding affinity.
  • Testing responses to N,N-Dimethylformamide and retinoic acid.

Main Results:

  • Isolated subclones exhibited refractoriness to TGF-beta's inhibitory effects on proliferation.
  • These resistant subclones maintained the ability to bind TGF-beta.
  • TGF-beta-induced increases in fibronectin and decreases in c-myc expression were attenuated in resistant subclones.
  • Refractoriness was specific to TGF-beta, as other agents like N,N-Dimethylformamide and retinoic acid still inhibited proliferation.

Conclusions:

  • Spontaneously arising resistance to TGF-beta in MOSER colon carcinoma cells can occur.
  • This resistance is specific for TGF-beta and does not affect responses to other differentiation-inducing agents.
  • The findings highlight the complexity of TGF-beta signaling pathways and potential mechanisms of therapeutic resistance in colon cancer.

Related Concept Videos